MARKET

HCM

HCM

Hutchmed (China) Limited
NASDAQ
15.64
-0.08
-0.51%
After Hours: 15.60 -0.04 -0.26% 17:40 02/26 EST
OPEN
15.55
PREV CLOSE
15.72
HIGH
15.69
LOW
15.25
VOLUME
47.77K
TURNOVER
0
52 WEEK HIGH
20.73
52 WEEK LOW
10.68
MARKET CAP
2.73B
P/E (TTM)
-78.4353
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at HCM last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at HCM last week (0212-0216)?
Weekly Report · 02/19 09:32
Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Airbnb, Inc. Shares fell in today's pre-market trading after the company reported fourth-quarter financial results. The Nasdaq futures trading higher by around 80 points on Wednesday. QuidelOrtho Corporation shares dipped 32.6% after reporting worse-than-expected results. U.S. Stock futures were higher this morning.
Benzinga · 02/14 09:55
Weekly Report: what happened at HCM last week (0205-0209)?
Weekly Report · 02/12 09:29
I-Mab to divest Chinese assets amid rising geopolitical tensions
Healthcare I-Mab to divest Chinese assets amid rising geopolitical tensions. U.S. Biopharma firm to divest the company's assets and business operations in China. The move follows bipartisan legislation introduced in Congress to restrict federal funds to Chinese firms. Biotechs with roots in China have sharply underperformed over the past six months.
Seeking Alpha · 02/07 16:28
HUTCHMED Presented Phase III Data On Fruquintinib In Second-Line Gastric Cancer At ASCO Plenary Series Session
Fruquintinib plus paclitaxel was well-tolerated with a safety profile consistent with expectations. The drug could be a promising second-line treatment option for patients with advanced gastric or gastroesophageal adenocarcinoma.
Benzinga · 02/07 05:36
Maintaining Hold on HUTCHMED: Mixed FRUTIGA Results and Fair Valuation Limit Upside
TipRanks · 02/07 04:36
Weekly Report: what happened at HCM last week (0129-0202)?
Weekly Report · 02/05 09:31
More
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Webull offers HUTCHMED (China) Ltd (ADR) stock information, including NASDAQ: HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.